Why did AbCellera Biologics stock fall on 8 October?
Written after the close on
AbCellera Biologics −6.31%
AbCellera Biologics fell sharply as AI drug-discovery enthusiasm cooled. Over the last five trading days AbCellera Biologics fell sharply, moving against both a clearly rising broad market and a slightly higher healthcare sector, after touching a new one-year high early in the stretch on excitement about AI-driven drug discovery and expanding biotech opportunities. The pullback looks like profit-taking after that run rather than a company-specific setback, since the news in the window was mostly upbeat industry forecasts for AI in drug discovery — projections of the market growing at roughly a quarter or more a year — which are third-party estimates for the whole field, not revenue for any one company. The next thing to watch is the early-November earnings report.
Next report: · Add to calendar · Google Calendar
Open AbCellera Biologics's chart